ACVR2B/Fc counteracts chemotherapy-induced loss of muscle and bone mass

Chemotherapy promotes the development of cachexia, a debilitating condition characterized by muscle and fat loss. ACVR2B/Fc, an inhibitor of the Activin Receptor 2B signaling, has been shown to preserve muscle mass and prolong survival in tumor hosts, and to increase bone mass in models of osteogene...

Descripción completa

Detalles Bibliográficos
Autores principales: Barreto, Rafael, Kitase, Yukiko, Matsumoto, Tsutomu, Pin, Fabrizio, Colston, Kyra C., Couch, Katherine E., O’Connell, Thomas M., Couch, Marion E., Bonewald, Lynda F., Bonetto, Andrea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5665981/
https://www.ncbi.nlm.nih.gov/pubmed/29089584
http://dx.doi.org/10.1038/s41598-017-15040-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5665981/
https://www.ncbi.nlm.nih.gov/pubmed/29089584
http://dx.doi.org/10.1038/s41598-017-15040-1

Ejemplares similares